Gilenya (fingolimod) - Important Safety Information from Novartis Ireland Limited as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 19/11/2013

 

Problem Or Issue:
Important Safety Information communication from Novartis Ireland Limited on haemophagocytic syndrome reported in patients treated with Gilenya (fingolimod).   

Important Safety Information ­- Gilenya (fingolimod)


« Back